Published in Science on September 03, 1993
Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet (2008) 7.07
IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A (2003) 5.09
Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet (2009) 4.97
Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A (2000) 3.48
Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A (1997) 2.56
CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A (1996) 2.38
Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med (1996) 2.30
Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A (1995) 2.06
Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A (1997) 1.95
The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J Exp Med (2001) 1.86
CD40 and autoimmunity: the dark side of a great activator. Semin Immunol (2009) 1.80
Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci U S A (1995) 1.71
Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med (2010) 1.68
Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest (2001) 1.59
Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol (1996) 1.56
The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future. J Autoimmun (2007) 1.55
Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther (2008) 1.54
Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest (1994) 1.41
Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med (1995) 1.37
Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci U S A (2000) 1.36
Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci U S A (1997) 1.35
Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin Invest (1997) 1.32
From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet (2010) 1.32
Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther (2003) 1.29
CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J Clin Invest (1998) 1.22
Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest (1999) 1.22
The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J Clin Invest (2000) 1.19
Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A (2000) 1.16
CD4+ T cells from collagen-induced arthritic mice are essential to transfer arthritis into severe combined immunodeficient mice. Clin Exp Immunol (1994) 1.09
Disruption of the CD40-CD40 ligand system prevents an oxygen-induced respiratory distress syndrome. Am J Pathol (1998) 1.08
Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology (2004) 1.08
CD40 expression by human peripheral blood eosinophils. J Clin Invest (1996) 1.07
Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest (2002) 1.07
Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy. J Clin Invest (1995) 1.04
Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction. Immunology (1997) 1.02
FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice. Naunyn Schmiedebergs Arch Pharmacol (2006) 1.01
CD40: novel association with Crohn's disease and replication in multiple sclerosis susceptibility. PLoS One (2010) 1.01
The random inactivation of the X chromosome carrying the defective gene responsible for X-linked hyper IgM syndrome (X-HIM) in female carriers of HIGM1. J Clin Invest (1994) 1.01
The role of polar interactions in the molecular recognition of CD40L with its receptor CD40. Protein Sci (1998) 0.99
Vascular cell adhesion molecule-1 (VCAM-1) blockade in collagen-induced arthritis reduces joint involvement and alters B cell trafficking. Clin Exp Immunol (2002) 0.99
Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis. Ann Rheum Dis (2000) 0.98
Therapeutic effect of Linum usitatissimum (flaxseed/linseed) fixed oil on acute and chronic arthritic models in albino rats. Inflammopharmacology (2010) 0.96
The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease. Am J Pathol (2010) 0.96
T cell clones from an X-linked hyper-immunoglobulin (IgM) patient induce IgE synthesis in vitro despite expression of nonfunctional CD40 ligand. J Exp Med (1994) 0.95
Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction. J Clin Invest (2000) 0.94
Human genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signaling pathway. PLoS Genet (2013) 0.93
The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells. J Exp Med (1996) 0.93
Targeting CD40L: a promising therapeutic approach. Clin Diagn Lab Immunol (2004) 0.92
CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol (2008) 0.92
High distribution of CD40 and TRAF2 in Th40 T cell rafts leads to preferential survival of this auto-aggressive population in autoimmunity. PLoS One (2008) 0.92
The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases. Clin Exp Immunol (2011) 0.92
A Rac1 inhibitory peptide suppresses antibody production and paw swelling in the murine collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther (2010) 0.91
Negative regulation of NF-κB and its involvement in rheumatoid arthritis. Arthritis Res Ther (2011) 0.89
Acquired, but not innate, immune responses to Streptococcus pneumoniae are compromised by neutralization of CD40L. Infect Immun (2000) 0.88
The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy. Clin Dev Immunol (2011) 0.88
CD40 glycoforms and TNF-receptors 1 and 2 in the formation of CD40 receptor(s) in autoimmunity. Mol Immunol (2010) 0.87
Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis? Br J Ophthalmol (1995) 0.86
Immunization with T cell receptor V beta chain peptides deletes pathogenic T cells and prevents the induction of collagen-induced arthritis in mice. J Clin Invest (1996) 0.86
Interleukin-15 up-regulates the expression of CD154 on synovial fluid T cells. Immunology (2000) 0.85
Immunological cell type characterization and Th1-Th17 cytokine production in a mouse model of Gaucher disease. Mol Genet Metab (2012) 0.85
Association of SNPs of CD40 gene with multiple sclerosis in Russians. PLoS One (2013) 0.85
Non-canonical NF-κB signaling in rheumatoid arthritis: Dr Jekyll and Mr Hyde? Arthritis Res Ther (2015) 0.84
The roles of IFN-γ versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblasts. Mod Rheumatol (2013) 0.84
Upregulation of CD40 expression on endothelial cells infected with human cytomegalovirus. J Virol (2002) 0.84
Elevated serum levels of soluble CD154 in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J (2008) 0.84
Genetic regulation of T regulatory, CD4, and CD8 cell numbers by the arthritis severity loci Cia5a, Cia5d, and the MHC/Cia1 in the rat. Mol Med (2007) 0.83
CD40 interacts directly with RAG1 and RAG2 in autoaggressive T cells and Fas prevents CD40-induced RAG expression. Cell Mol Immunol (2013) 0.83
Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clin Exp Immunol (2013) 0.82
CD40/CD40 ligand interactions in immune responses and pulmonary immunity. Nagoya J Med Sci (2011) 0.81
CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis. Clin Dev Immunol (2011) 0.81
Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis. J Clin Invest (2002) 0.80
NF-κB and Rheumatoid Arthritis: Will Understanding Genetic Risk Lead to a Therapeutic Reward? For Immunopathol Dis Therap (2013) 0.79
The Contribution of CD40/CD40L Axis in Inflammatory Bowel Disease: An Update. Front Immunol (2015) 0.79
Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant (2014) 0.78
Decrease of CD154 intensity on peripheral CD4+ T cells in autoimmune thyroid disease. Clin Exp Immunol (2004) 0.78
Association of CD40 Gene Polymorphisms with Susceptibility to Neuromyelitis Optica Spectrum Disorders. Mol Neurobiol (2016) 0.78
Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol (2017) 0.77
A polymorphic CD40 ligand (CD154) molecule mediates CD40-dependent signalling but interferes with the ability of soluble CD40 to functionally block CD154:CD40 interactions. Immunology (2000) 0.77
Tolerogenic activity of polyethylene glycol-conjugated lysozyme distinct from that of the native counterpart. Immunology (1998) 0.77
Hesperidin inhibits collagen-induced arthritis possibly through suppression of free radical load and reduction in neutrophil activation and infiltration. Rheumatol Int (2012) 0.77
CD40-CD40 ligand disruption does not prevent hyperoxia-induced injury. Am J Pathol (2002) 0.77
Reduced T cell-dependent humoral immune response in microsomal prostaglandin E synthase-1 null mice is mediated by nonhematopoietic cells. J Immunol (2013) 0.76
Transient anti-CD40L co-stimulation blockade prevents immune responses against human bullous pemphigoid antigen 2: implications for gene therapy. J Invest Dermatol (2008) 0.76
T cells of lupus and molecular targets for immunotherapy. J Clin Immunol (1997) 0.76
High IgE in rheumatoid arthritis (RA) patients is complexed with anti-IgE autoantibodies. Clin Exp Immunol (1999) 0.76
Oxaprozin-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways. J Biomed Biotechnol (2009) 0.76
A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice. Diabetologia (2014) 0.76
X inactivation and immunocompetence in female carriers of the X-linked hyper-IgM syndrome. J Clin Invest (1994) 0.75
Attenuation of reactive oxygen/nitrogen species with suppression of inducible nitric oxide synthase expression in RAW 264.7 macrophages by bark extract of Buchanania lanzan. Pharmacogn Mag (2015) 0.75
Artesunate influences Th17/Treg lymphocyte balance by modulating Treg apoptosis and Th17 proliferation in a murine model of rheumatoid arthritis. Exp Ther Med (2017) 0.75
CD40L and Its Receptors in Atherothrombosis-An Update. Front Cardiovasc Med (2017) 0.75
Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol Rev (1979) 16.45
Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci U S A (1987) 12.15
CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 9.94
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med (1991) 8.78
Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science (1989) 7.78
Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in mouse and man. J Exp Med (1981) 6.82
T cell subsets defined by expression of Lyt-1,2,3 and Thy-1 antigens. Two-parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views. J Exp Med (1980) 6.62
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature (1996) 6.61
T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci U S A (1990) 6.19
The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol (1993) 5.65
CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci U S A (1989) 5.07
Visualization of specific B and T lymphocyte interactions in the lymph node. Science (1998) 5.04
Role of the CD28 receptor in T-cell activation. Immunol Today (1990) 4.89
A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A (1992) 4.77
T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol (1987) 4.76
Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science (1992) 4.53
Mice deficient for the CD40 ligand. Immunity (1994) 4.45
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 4.34
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1. J Virol (1988) 3.88
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med (1992) 3.77
Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science (1990) 3.74
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (1994) 3.73
Definition of a common leukocyte cell-surface antigen (Lp95-150) associated with diverse cell-mediated immune functions. J Immunol (1983) 3.70
Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. Proc Natl Acad Sci U S A (1990) 3.69
Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci U S A (1986) 3.68
Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol (1996) 3.56
Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation. J Immunol (1990) 3.51
CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med (2001) 3.51
How B and T cells talk to each other. Nature (1994) 3.37
Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol (1995) 3.34
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med (1997) 3.31
Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood (1988) 3.30
The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J (1991) 3.20
Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry. J Immunol (1986) 3.08
Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates. Nature (1992) 2.97
gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med (1994) 2.87
A role for CD5 in TCR-mediated signal transduction and thymocyte selection. Science (1995) 2.84
CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. J Immunol (1990) 2.84
In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med (1993) 2.72
Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med (1993) 2.71
Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes. Proc Natl Acad Sci U S A (1987) 2.53
The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol (1993) 2.53
Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J Immunol (1985) 2.46
Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J Exp Med (1992) 2.42
B-cell growth factor (B-cell growth factor I or B-cell-stimulating factor, provisional 1) is a differentiation factor for resting B cells and may not induce cell growth. Proc Natl Acad Sci U S A (1985) 2.41
Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med (1996) 2.39
CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A (1996) 2.38
CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol (1995) 2.38
Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med (1994) 2.37
The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today (1994) 2.36
Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J Immunol (1992) 2.36
The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and alpha 2-6 sialyltransferase, CD75, on B cells. Cell (1991) 2.24
Isolation of a calcium-dependent 35-kilodalton substrate for the epidermal growth factor receptor/kinase from A-431 cells. J Biol Chem (1984) 2.21
Loss of CD45R (Lp220) represents a post-thymic T cell differentiation event. J Immunol (1988) 2.20
A human T lymphocyte differentiation marker defined by monoclonal antibodies that block E-rosette formation. J Immunol (1981) 2.20
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood (1998) 2.17
Expression of functional CD40 by vascular endothelial cells. J Exp Med (1995) 2.16
Identification and functional characterization of two distinct epitopes on the human T cell surface protein Tp50. J Immunol (1983) 2.13
Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression. J Immunol (1985) 2.11
Characterization and cloning of a novel glycoprotein expressed by stromal cells in T-dependent areas of peripheral lymphoid tissues. J Exp Med (1992) 2.11
Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A (1995) 2.06
Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem (1995) 2.05
A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. J Immunol (1986) 1.95
Ability of bacteria associated with chronic inflammatory disease to stimulate E-selectin expression and promote neutrophil adhesion. Infect Immun (1995) 1.95
CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci U S A (1994) 1.94
Mast cell degranulation breaks peripheral tolerance. Am J Transplant (2009) 1.94
CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today (1992) 1.93
Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome. Blood (1998) 1.89
Fibronectin-associated transforming growth factor. J Cell Physiol (1987) 1.89
Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J Immunol (1986) 1.89
Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc Natl Acad Sci U S A (1985) 1.89
Treatment of murine lupus with monoclonal anti-T cell antibody. J Immunol (1985) 1.87
The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J Exp Med (2001) 1.86
Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol (1995) 1.84